Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise

Euglycemic ketosis can occur in individuals with type 1 diabetes when multiple metabolic stressors converge; however, early recognition is challenging without dedicated ketone monitoring. We report a case of a 30-year-old woman with type 1 diabetes using automated insulin delivery and 10 mg empagliflozin who adopted a low-carbohydrate diet and increased physical activity while using continuous ketone monitoring (CKM) with a wearable ketone sensor (NCT06753994). Under these combined conditions, CKM detected persistent ketosis exceeding 1.0 mmol/L for 14 h, with a maximum concentration of 2.9 mmol/L, despite euglycemia on continuous glucose monitoring. CKM supported the timely identification of ketosis, guided appropriate carbohydrate and insulin treatment, and allowed real-time monitoring of recovery. This case illustrates how CKM can reveal clinically meaningful euglycemic ketosis and aid in early intervention, suggesting a potential role for CKM in mitigating diabetes ketoacidosis risk in individuals using sodium-glucose cotransporter-2 inhibitors or undertaking carbohydrate restriction and intense exercise.

Authors

Institutions

Publication Details

Journal
Diabetes Technology & Therapeutics
Published
2026-02-04
DOI
https://doi.org/10.1177/15209156261420167
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise

AHMAD HAIDAR, Melissa‐Rosina Pasqua, Elisabeth Lawton, Linden Perz et al.
Diabetes Technology & Therapeutics
Diet and metabolism studies
article

Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise

AHMAD HAIDAR, Melissa‐Rosina Pasqua, Elisabeth Lawton, Linden Perz, Michael Tsoukas
article en

Abstract

Euglycemic ketosis can occur in individuals with type 1 diabetes when multiple metabolic stressors converge; however, early recognition is challenging without dedicated ketone monitoring. We report a case of a 30-year-old woman with type 1 diabetes using automated insulin delivery and 10 mg empagliflozin who adopted a low-carbohydrate diet and increased physical activity while using continuous ketone monitoring (CKM) with a wearable ketone sensor (NCT06753994). Under these combined conditions, CKM detected persistent ketosis exceeding 1.0 mmol/L for 14 h, with a maximum concentration of 2.9 mmol/L, despite euglycemia on continuous glucose monitoring. CKM supported the timely identification of ketosis, guided appropriate carbohydrate and insulin treatment, and allowed real-time monitoring of recovery. This case illustrates how CKM can reveal clinically meaningful euglycemic ketosis and aid in early intervention, suggesting a potential role for CKM in mitigating diabetes ketoacidosis risk in individuals using sodium-glucose cotransporter-2 inhibitors or undertaking carbohydrate restriction and intense exercise.

Diabetes Technology & Therapeutics
McGill University Health Centre (CA), McGill University (CA)
Good health and well-being
Openalex Percentile: Top 64%
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise — AHMAD HAIDAR, Melissa‐Rosina Pasqua, et al. · Diabetes Technology & Therapeutics (2026) | TGRS Research Map | TGRS